Coherus Oncology Inc

Coherus Oncology Inc a biopharmaceutical company researches develops and commercializes immunotherapies to treat cancer in the United States The company develops UDENYCA a biosimilar to Neulasta a longacting granulocytecolony stimulating factor LOQTORZI a novel nextgeneration programmed death receptor1 inhibitor and Casdozokitug an investigational recombinant human immunoglobulin isotype IgG1 monoclonal antibody targeting interleukin 27 It also develops CHS114 an investigational highly specific human afucosylated IgG1 monoclonal antibody a chemokine receptor highly expressed on Treg cells in the tumor microenvironment TME and CHS1000 AntiILT4 monoclonal antibody for solid tumors In addition the company offers GSK4381562 an antibody targeting CD112R to treat tumor cells YUSIMRY a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor TNF in the body such as rheumatoid arthritis juvenile idiopathic arthritis psoriatic arthritis ankylosing spondylitis Crohns disease psoriasis and ulcerative colitis and CIMERLI a Lucentis biosimilar to treat neovascular agerelated macular degeneration macular edema following retinal vein occlusion diabetic macular edema diabetic retinopathy and myopic choroidal neovascularization It has a collaboration agreement with Junshi Biosciences for the codevelopment and commercialization of toripalimab agreement with Surface and Adimab LLC license agreements with Bioeq AG and Genentech Inc and Surface and Vaccinex Inc and outlicensing agreement with Novartis Institutes for Biomedical Research Inc and GlaxoSmithKline Intellectual Property No 4 Limited The company was formerly known as Coherus BioSciences Inc and changed its name to Coherus Oncology Inc in May 2025 The company was incorporated in 2010 and is based in Redwood City California